Four with Medical School ties are among 12 University of Michigan faculty and staff members recognized by the American Association for the Advancement of Science (AAAS) as 2023 fellows in recognition of their extraordinary achievements.

A new urine-based test addresses a major problem in prostate cancer: how to separate the slow growing form of the disease unlikely to cause harm from more aggressive cancer that needs immediate treatment.

New map of the ovary provides a deeper understanding of how oocytes interact with the surrounding cells during the normal maturation process, and how the function of the follicles may break down in aging or fertility related diseases.

At-home test can detect tumor DNA fragments in urine samples, providing a non-invasive alternative to traditional blood-based biomarker tests

How lipid mediators -- potent regulators of the immune response after an injury -- varied with the acute loss of a large volume of skeletal muscle, also known as volumetric muscle loss (VML) is the focus of new research from the University of Michigan.

Through a $4.17M NIH grant, a team of biomedical engineers, medical clinicians and data scientists from the Max Harry Weil Institute for Critical Care Research and Innovation is collaboratively researching ways to develop a portable, non-invasive breathalyzer-type device and corresponding algorithm to quickly and accurately diagnose acute respiratory distress syndrome (ARDS).

Metabolism pathways make tumors sensitive or resistant to treatments. A collaborative group leverages these avenues to explore the growing foundation of new potential therapies

Michigan Medicine researchers looked into a drug in development to treat prostate cancer called proxalutamide, which works by blocking an enzyme called TMPRSS2 (transmembrane protease, serine 2) that is regulated by androgen receptors, as a potential therapeutic for COVID.

A study from clinicians and researchers at the University of Michigan Rogel Cancer Center reveals findings from over 800 clinical assays performed for kidney patients with MiTF family gene mutations.

A collaborative research effort led by the University of Michigan and the Icahn School of Medicine at Mount Sinai has resulted in a nasal vaccine adjuvant that stops infection in both young and old mice.

There are 13 U-M graduate medical education programs ranked in the top 10 by Doximity.

An interview with Dr. Steven Kunkel on research at U-M Medical School.

Gene therapy for hemophilia B, a rare bleeding disorder, reinforces lower bleeding rates and improved outcomes.

Lisa H. Harris, M.D., Ph.D., named Thurnau Professor; second-ever from UMMS

Russell Ryan, MD, and his team’s discovery appears to address longstanding mysteries about mutations found in B-cell acute lymphoblastic leukemia